Leadless cardiac pacing: Results from a large single-centre experience

Background: The efficacy and safety of leadless cardiac pacing as an alternative to conventional transve-nous cardiac pacing in selected patients have been widely reported. Aim: To report the experience of a high-volume implantation centre with older and new generations of leadless pacemakers. Methods: This retrospective observational study included the first consecutive 400 patients who under-went implantation of a leadless pacemaker in our centre. Complications and electrical parameters were evaluated during follow-up, comparing patients implanted with first-generation (MicraTM VR) and second-generation (MicraTM AV) leadless pacemakers (Medtronic, Minneapolis, MN, USA). Data were collected by a review of medical files. Results: Among 400 procedures, there were 328 MicraTM VR pacemakers and 72 MicraTM AV pacemakers implanted, followed for a median of 16 months (694 patient-years). The mean age was 77 years and both groups had a high burden of co-morbidities. Implantation success rate was 99.5%. A total of 87.5% of patients were discharged the day after the procedure. The pacing threshold remained stable and < 2 V in 96.5% of all patients. The perioperative complication rate at 30 days was 3.5%. Outcomes were similar between the two groups. Conclusion: Leadless cardiac pacing is a safe and efficient alternative to conventional transvenous cardiac pacing.& COPY; 2023 Elsevier Masson SAS. All rights reserved.